CMO/CDMO Industry Analysis in Brazil

Brazil CMO/CDMO Market Size and Share Forecast 2025 to 2035

The CMO/CDMO Industry Analysis in Brazil is estimated to be valued at USD 736.1 million in 2025 and is projected to reach USD 948.3 million by 2035, registering a compound annual growth rate (CAGR) of 2.6% over the forecast period.

Quick Stats for CMO/CDMO Industry Analysis in Brazil

• CMO/CDMO Industry Analysis in Brazil Industry Value (2025): USD 736.1 million
• CMO/CDMO Industry Analysis in Brazil Forecast Value (2035): USD 948.3 million
• CMO/CDMO Industry Analysis in Brazil Forecast CAGR: 2.6%
• Leading Segment in CMO/CDMO Industry Analysis in Brazil in 2025: Stand-Alone Services (34.7%)
• Key Growth Region in CMO/CDMO Industry Analysis in Brazil: North America, Asia-Pacific, Europe
• Top Key Players in CMO/CDMO Industry Analysis in Brazil: Patheon N.V. (Thermo Fisher Scientific, Inc.), Lonza AG, Unither Pharmaceuticals, Catalent Inc., Fagron, Eurofarma, Pfizer CentreOne, NUVISAN, Societal CDMO, Bio-Manguinhos, Biotimize, Pierre Fabre group, Ajinomoto Co., Inc.

Metric	Value
CMO/CDMO Industry Analysis in Brazil Estimated Value in (2025 E)	USD 736.1 million
CMO/CDMO Industry Analysis in Brazil Forecast Value in (2035 F)	USD 948.3 million
Forecast CAGR (2025 to 2035)	2.6%

Rationale for Segmental Growth in the CMO/CDMO Industry in Brazil

The CMO/CDMO industry in Brazil is experiencing robust growth. Increasing pharmaceutical outsourcing, rising biologics development, and expansion of contract manufacturing capabilities are driving demand. Current dynamics are characterized by the adoption of both small and large molecule production services, regulatory support for biotechnology manufacturing, and strategic partnerships between local and global players.

Investment in state-of-the-art facilities, capacity expansion, and compliance with international quality standards are enhancing operational efficiency. The future outlook is shaped by growing demand for specialized manufacturing services, technological advancements in drug development, and the expansion of biologics pipelines, which are expected to elevate outsourcing requirements.

Growth rationale is anchored on the ability of CMOs/CDMOs to provide flexible, cost-effective, and scalable manufacturing solutions, support regulatory compliance, and accelerate time-to-market for pharmaceutical products Continued focus on high-quality production infrastructure, innovation in process development, and strategic collaborations is expected to sustain market expansion and strengthen Brazil’s position in the global contract manufacturing landscape.

Segmental Analysis

Insights into the Services Segment

The stand-alone services segment, holding 34.7% of the services category, has been leading due to its ability to provide flexible and specialized manufacturing and development support without long-term integration commitments. Its adoption has been supported by pharmaceutical companies seeking cost-efficient solutions and rapid scale-up capabilities.

Regulatory compliance and high-quality standards have reinforced confidence in these services. The segment has benefited from strategic investments in process development, analytical capabilities, and technology transfer support, ensuring operational efficiency and reliability.

Growth is further driven by increasing outsourcing trends in biologics and complex therapeutics Continued focus on expanding service offerings, improving turnaround times, and enhancing client partnerships is expected to maintain the segment’s market share and reinforce its competitive position in the Brazilian CMO/CDMO landscape.

Insights into the Product Segment

The large molecule segment, representing 29.4% of the product category, has maintained dominance due to increasing biologics development and the need for specialized manufacturing expertise. Its adoption has been supported by demand for monoclonal antibodies, recombinant proteins, and other complex therapeutics.

Advanced production processes, adherence to quality standards, and scalability have reinforced preference among pharmaceutical developers. Technological enhancements in purification, formulation, and analytical testing have improved production efficiency and product consistency.

The segment’s growth is further underpinned by investment in state-of-the-art bioprocessing facilities and regulatory alignment with international standards Continued pipeline expansion for biologics and increased outsourcing of large molecule production are expected to sustain the segment’s market share and drive overall industry growth.

Insights into the Expression System Segment

The mammalian expression system segment, holding 41.2% of the expression system category, has emerged as the leading platform due to its capability to produce complex and highly functional proteins with human-compatible post-translational modifications. Adoption has been driven by its relevance in monoclonal antibody production, advanced therapeutics, and regulatory acceptance for biologics.

Process optimization, facility capabilities, and quality control measures have reinforced its market leadership. Investments in cell line development, bioreactor optimization, and analytical testing have enhanced efficiency, yield, and consistency.

Continued innovation in mammalian expression technologies, along with increasing demand for biologics and outsourced manufacturing, is expected to maintain the segment’s dominance and support long-term growth in Brazil’s CMO/CDMO industry.

Historical Analysis of Brazil CMO/CDMO Industry (2020 to 2024) vs. Forecast (2025 to 2035)

The Brazil CMO/CDMO business recorded a decent CAGR of 2.0% in the historical period from 2020 to 2025. The value for the CMO/CDMO business in Brazil was around 1.2% of the total USD 56,660.60 million of the global CMO/CDMO business.

The growing pharmaceutical sector is the main factor spurring the Brazil CMO/CDMO business landscape. Increasing approval of manufacturing facilities is set to drive growth.

The total production capacity in Brazil rises as more manufacturing facilities are approved. The increased demand for outsourcing services would enable CMOs and CDMOs to take on additional clients and projects.

The approval of multiple manufacturing facilities, such as those for sterile injectables, biologics, or specialized formulations, can increase the variety of services provided by CMOs and CDMOs. Due to this variety, pharmaceutical companies can select partners who meet their particular requirements.

• For instance, in August 2025, Granules India Limited achieved approval from the Brazilian Health Regulatory Agency (ANVISA) for its Bonthapally facility, located in Bonthapally Village, in recognition of its compliance with Good Manufacturing Practices guidelines.

Manufacturing facilities would become more competitive in the global business landscape as they receive approval. CMOs/CDMOs that can show compliance with international regulatory standards would draw clients from other nations looking for dependable manufacturing partners in addition to Brazil.

The Brazil CMO/CDMO ecosystem has begun to place a lot of emphasis on the manufacturing of biologics and biosimilars. The complexity of these products frequently necessitates specialized production capabilities, and this business category has seen tremendous expansion.

The government of Brazil has also started several programs to encourage expansion in the biotechnology and pharmaceutical sectors. These include tax breaks, research grants, and other forms of assistance to promote industrial investment and innovation.

CMOs and CDMOs in Brazil have started to focus more on research & development services and offering their experience in technological development. They are also aiming to understand analytical testing and process optimization in addition to typical manufacturing services

Trends, Opportunities, and Challenges in the Brazil CMO/CDMO Landscape

The table below provides the latest trends observed in the Brazil CMO/CDMO space, growth obstacles, and upcoming opportunities. Business strategies for pushing CMO/CDMO sales in Brazil would enable stakeholders to invest in the right area and gain profit.

Attributes	Key Factors
Latest Trends	Pharmaceutical and biotechnology companies are progressively outsourcing their manufacturing requirements to CMOs and CDMOs. This trend is driven by aspects such as cost efficiency, access to expert knowledge, and the need for flexible manufacturing capabilities. Biologics and biosimilar manufacturing is a rising segment in the Brazil CMO/CDMO business. This is due to the growing demand for these compound therapies, which often need specialized manufacturing abilities. Regulatory acquiescence and adherence to global quality standards remain important aspects for both CMOs and CDMOs. Companies have focused on upholding high-quality manufacturing processes to meet worldwide regulatory requirements. CMOs and CDMOs are capitalizing on advanced technology and automation to increase efficiency, reduce costs, and improve the quality of the manufacturing process. This includes the adoption of advanced manufacturing systems and equipment. Environmental sustainability has become a significant consideration in the CMO/CDMO space. Businesses are adopting environmentally friendly methods and technologies to diminish their impact on the environment and align with global sustainable development goals.
Upcoming Opportunities	High-quality manufacturing by CMO/CDMOs can create a lucrative opportunity in the Brazil CMO/CDMO business. Pharmaceutical companies in Brazil can gain from luring foreign customers looking for partners with a reputation for top-notch production. Customers from all around the world support CMOs/CDMOs that can reliably create pharmaceuticals that adhere to global quality standards, such as Good Manufacturing Practices (GMP), thereby creating new opportunities in Brazil. In a competitive sector, superior manufacturing sets CMOs/CDMOs in particular. The assurance of product quality and safety is valued by companies searching for outsourcing partners, and they are willing to pay more for such services. Pharmaceutical companies that outsource manufacturing aim to reduce risks related to supply chain interruptions, product quality, and regulatory compliance. Reducing these risks involves collaborating with CMOs/CDMOs recognized for high-quality production. Specializing in specific therapeutic areas is the reason for boosting the CMO/CDMO demand in Brazil over the forecast period. Utilizing their experience and expertise, specialized CMOs/CDMOs can accelerate the drug development process. This is expected to result in shorter development cycles, which can hasten the time it takes for pharmaceutical businesses to sell their drugs.
Challenges	The Brazil CMO/CDMO business faces a significant restraint in the form of quality assurance, compliance challenges, and supply chain vulnerabilities. The regulatory environment in Brazil frequently necessitates significant documentation through records of production operations and quality control procedures. It can be time- and resource-consuming to ensure accurate and detailed documentation. It is possible that smaller CMOs/CDMOs in Brazil will run into resource issues while attempting to build and maintain effective quality assurance and compliance procedures. Their capacity to compete with bigger, more seasoned players can be limited as a result. Regular compliance inspections by regulatory bodies can hinder productivity and take resources away from it. Findings of non-compliance can result in fines, such as halts in production. Dependence on imported raw materials and active pharmaceutical ingredients (APIs) can put CMOs and CDMOs at risk for supply interruptions brought on by factors, including trade restrictions, transportation problems, or shifts in the dynamics of the world's supply chain.

Analysis of Key Regions Supporting CMO/CDMO Growth in Brazil

The table below shows the share of the top 5 countries for the review period from 2025 to 2035. South and North Brazil are expected to remain dominant by exhibiting CAGRs of 4.5% and 4.9%, respectively. The Central-west and Northeast Brazil are projected to follow with CAGRs of 3.8% and 3.1%, respectively.

Growth Outlook by Key Region

Regions	Value CAGR
Southeast Brazil	2.3%
Northeast Brazil	3.1%
Central-west Brazil	3.8%
South Brazil	4.5%
North Brazil	4.9%

Increasing Research and Development in Southeast Brazil to Drive Demand

Growth in Southeast Brazil’s pharmaceutical sector is expanding steadily. Due to population expansion and improved access to healthcare, there is an increase in local demand for pharmaceuticals and other medical products.

The Southeast area of Brazil is benefiting from initiatives the government has put in place to encourage pharmaceutical business expansion. This includes financial incentives and tax breaks for businesses setting up shop in the region.

Southeast Brazil dominated the CMO/CDMO business and generated a 68.6% share in 2025. It is projected to continue experiencing high growth throughout the forecast period.

The economic center of Brazil is in the southeast, which is home to important cities, such as Sao Paulo and Rio de Janeiro. It is a popular site for CMOs and CDMOs to serve these clients because of its significant industrial base and the large number of pharmaceutical and biotech companies that call it home.

Prestigious universities and research institutions in Southeast Brazil offer a skilled labor pool and chances for collaboration between CMOs/CDMOs and academia on research & development projects. Also, several CMOs/CDMOs based in Southeast Brazil have expanded their operations globally, enabling them to serve clients both domestically and internationally.

Increasing Focus on Biotechnology to Surge Demand in Northeast Brazil

A handful of states in Northeast Brazil, such as Pernambuco, have taken special initiatives to draw in investments in the fields of biotechnology and life sciences. This has caused a cluster of biotech businesses to expand, opening doors for CMOs and CDMOs that focus on biologics.

Biotechnology and pharmaceutical research and development have received more attention in the region. This involves the development of formulations, analytical testing, and process optimization, areas in which CMOs and CDMOs can be particularly skilled.

Northeast Brazil dominates the Brazil CMO/CDMO business and held a 19.8% share in 2025. It is projected to continue experiencing high growth throughout the forecast period. Northeast Brazil has special environmental features or natural resources that make biopharmaceutical research and development possible.

Northeast Brazil is also the perfect location for companies focused on biotech and their manufacturing partners backed by these resources. Also, the region is home to eminent research facilities and academic hubs with a focus on biotechnology and pharmaceuticals.

They can promote cooperation between these institutions and CMOs/CDMOs. Such collaborations are frequently necessary to expand research and development initiatives.

Rising Investments in Infrastructure Fuel Sales in Central-west Brazil

Central-west Brazil held about a 5.1% share of the Brazil CMO/CDMO business in 2025. It is projected to increase during the forecast period.

Central-west Brazil's center geographic location offers a logistical advantage, enabling effective pharmaceutical product distribution to multiple regions across Brazil and adjacent nations. For CMOs and CDMOs aiming to serve a large space, this can be a crucial draw.

Investments in infrastructure, including transportation networks and industrial parks, can further enhance the region's attractiveness for pharmaceutical manufacturing and supply chain operations. The government supports domestic medicinal product production.

CMOs and CDMOs in the region would have the chance to serve the home ecosystem and export goods. Several colleges and research facilities in Central-west Brazil offer a pool of qualified workers in fields related to pharmaceutical development and manufacturing. CMOs and CDMOs can benefit from this in terms of hiring new personnel.

Brazil CMO/CDMO Industry Analysis by Top Investment Segments

The table below signifies leading sub-categories under product, expression, and company size categories in the Brazil CMO/CDMO business. Stand-alone services are expected to dominate the ecosystem for Brazil CMO/CDMO at a CAGR of 3.4% by 2035. Under the company size category, the mid-sized segment is projected to lead the Brazil CMO/CDMO space with a CAGR of 2.3% by 2035.

Growth Outlook by Key Segments

Segment	Value CAGR
Stand-alone Services (Services)	3.4%
API Substrate (Product)	1.9%
Mid-sized (Company Size)	2.3%
Mammalian (Expression System)	2.7%
Commercial (Scale of Operation)	2.9%

Stand-alone Services are to be Preferred Amid High Cost-cutting Needs

Stand-alone services under the service category held a share of 42.5% in 2025. It is expected to remain at the forefront over the forecast period.

Stand-alone services focus on specific aspects of drug development and manufacturing, such as formulation development, analytical testing, or sterile manufacturing. This specialization can attract companies seeking expertise in a particular area.

Companies decide to use stand-alone services to cut costs by outsourcing only a portion of the production or development of drugs while maintaining control over the remaining portions. This factor is anticipated to lead the stand-alone service segment in the Brazil CMO/CDMO business.

API Substrates are the Most Popular Type of Product

API substrate under the product category held a considerable share of 41.4% in 2025. The main components of pharmaceutical formulations are APIs.

APIs, often referred to as the dynamic components of medications, underlie their therapeutic effectiveness. The process of crafting APIs holds a pivotal role in the production of pharmaceuticals, marking a critical step in the journey of creating therapeutic solutions.

Pharmaceutical companies find it more affordable to outsource API production. The volume and efficiency of CMOs and CDMOs would allow them to create APIs more cheaply than in-house labs.

Mammalian Expression Systems to be Chosen Primarily by Suppliers

For the manufacturing of biologics, such as monoclonal antibodies, recombinant proteins, and vaccines, mammalian expression systems are frequently chosen. Due to their success in treating a wide range of ailments, biologics have grown in terms of popularity in the operating of the pharmaceutical sector.

Mammalian expression systems are set to be necessary for the manufacturing of several advanced and sophisticated medicines, including cell and gene therapies. These treatments are projected to make up a rapidly expanding area for pharmaceuticals. This factor is expected to stimulate the mammalian segment over the forecast timeline.

Competitive Landscape and Strategic Positioning

Geographic expansions are a priority for leading CMO/CDMO companies in Brazil as they work to create new product lines and expand their global consumer base. Expansion and acquisition among key companies or brands is the leading strategy of manufacturers such as Catalent and Fragon.

They aim to enhance their presence in the business landscape and compete with other players during the forecast period. Following are a handful of recent developments:

For instance,

• In May 2024, Lonza inaugurated a new laboratory, marking a significant step in the Swiss Contract Development and Manufacturing Organization's (CDMO) strategy to bolster its presence in North America. It also plans to advance its Early Development Services (EDS) segment.
• In February 2025, Pharma Nobis, LLC completed its acquisition of Fagron’s contract manufacturing business and manufacturing facility.
• In August 2025, Catalent made an announcement regarding its acquisition of Metrics Contract Services. Metrics Contract Services is a specialized Contract Development and Manufacturing Organization (CDMO) known for its 333,000-square-foot facility located in Greenville.

Scope and Coverage of the Brazil CMO/CDMO Market Report

Attribute	Details
Brazil CMO-CDMO Revenue (2025)	USD 736.1 million
Projected Brazil CMO-CDMO Revenue (2035)	USD 948.3 million
Value-based CAGR (2025 to 2035)	2.6%
Forecast Period	2025 to 2035
Historical Data Available for	2020 to 2025
Business Analysis	Value (USD million)
Key Regions Covered	North Brazil; Northeast Brazil; Central-west Brazil; Southeast Brazil; and South Brazil
Key Segments Covered	Services, Product, Expression System, Company Size, Scale of Operation, Region
Key Companies Profiled	Lonza AG; Unither Pharmaceuticals; Catalent Inc.; Fagron; Eurofarma; Pfizer CentreOne; Patheon N.V. (Thermo Fisher Scientific, Inc.); NUVISAN; Societal CDMO; Bio-Manguinhos; Biotimize; Pierre Fabre group; Ajinomoto Co., Inc.

Top Segments Studied in the Brazil CMO/CDMO Market

By Services:

• Stand-alone Services
  • Cell Line Development
  • Development and Bio Manufacturing
  • Analytical Services
  • Fill Finish
  • Packaging
  • Clinical Supply Services
• Integrated Development
• Scale-up and Tech Transfer
• Technology and Innovation
• Quality Control and Quality Assurance
• Regulatory Assistance

By Product:

• API Substrate
• Large Molecule
  • Monoclonal Antibodies
  • Antibody Fragments
  • Recombinant Therapeutic Proteins
  • Viral Vector
  • Cell and Gene Therapy
  • Vaccine
  • Peptides
  • Antibody Drug Conjugates (ADCs)
• Small Molecule

By Expression System:

• Mammalian
• Microbial
  • Bacteria
  • Yeast

By Company Size:

• Small
• Mid-sized
• Large
• Very Large

By Scale of Operation:

• Preclinical
• Clinical
  • Phase I
  • Phase II
  • Phase III
• Commercial

By Region:

• North Brazil
• Northeast Brazil
• Central-west Brazil
• Southeast Brazil
• South Brazil